CORPUS CHRISTI, Texas and OKLAHOMA CITY, April 22, 2004 (PRIMEZONE) -- Donald S. Robbins, CEO of Consortium Service Management Group, Inc. (OTCBB:CTUM), announced today its subsidiary, Live Tissue Connect, Inc., will perform US demonstrations using its platform live-biological-tissue bonding technology at the University of Louisville, Louisville, Kentucky next month.
The demonstrations will be a private showing to a select group of invited guests that includes a medical device company, venture capital firm, medical and industry professionals. The demonstrations will include smokeless and bloodless reconnection of organs using our platform radiofrequency technology that provides a leak-proof bond through radiofrequency welded fusion. Demonstrations will include end-to-end and end-to-side reconnection of intestine, stomach reconnection, liver resection, spleen, gall blabber, large blood vessels and surgery techniques for other organs. The demonstration will also include burst strength comparisons.
Robbins said, "CTUM is pleased to demonstrate the technology in a major US medical research facility. This is our first step in bringing the technology to the US and Western World, beginning the process of filing for US and Western regulatory approval and commercializing the company's live-biological-tissue bonding technology product."
In Ukraine, over 2,000 successful human surgeries in clinical trials have been completed on various organs using a number of types of procedures. Today, surgeons at four Ukraine hospitals and clinics are using the tissue bonding technology in clinical trials and performing between 80 and 100 new surgeries each month for open and laparoscopic surgical procedures and techniques. The procedures so far have involved the bonding and reconnecting of incised or separated human tissues in the following body areas -- nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, fallopian tube, ovary and testicles, dura-matter -- while restoring the normal function of the body organ or tissue.
The tissue bonding device bonds and reconnects living soft biological tissue using a radiofrequency fused bond without the use of foreign matters or conventional wound closing devices such as sutures, staples, sealant, or glues. The technology leaves little or no scar tissue visible to the naked eye after a few months, said Robbins. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CTUM patented, smokeless, leak-proof technology bonds by welded fusion and reconnects incised tissue and avoids charring, searing and necrosis, using low heat delivery method aimed at restoration of the normal functions of the live organs and tissue.
United States and Australia patents have been issued with other foreign patents pending, Robbins said. CTUM maintains a team of more than 30 academicians, professors, researchers, surgeons, engineers, technicians and clinical test facilities in Ukraine and has offices in Corpus Christi, Texas; Oklahoma City, Oklahoma and Kiev, Ukraine.
CTUM owns the technology and exclusive world rights to the required medical device through Live Tissue Connect Inc., a subsidiary corporation formed for the development and exploitation of the medical device platform technology.
CSMG's stock is quoted on the Internet at www.otcbb.com. Its website is www.ctum.com, and its E-mail address is publicrelations@ctum.com .